Contributors: Institut Pasteur de la Guyane; Réseau International des Instituts Pasteur (RIIP); Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane); Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre / Abymes Guadeloupe -CHU de Fort de France-Centre Hospitalier Andrée Rosemon Cayenne, Guyane Française; Centre Hospitalier Andrée Rosemon Cayenne, Guyane Française; Centre Hospitalier de l'Ouest Guyanais Franck Joly (Saint-Laurent-du-Maroni); Unité des Maladies Infectieuses et Tropicales Cayenne, Guyanne Française; This work was funded by the Institut Pasteur de la Guyane. It has also benefited from a European commission REGPOT-CT-2011-285837-STRonGer grant within the FP7; The authors thank Nathalie Jolly from the Institut Pasteur Clinical Research Department (PIRC, Pôle Intégré de Recherche Clinique) for her help in the ethical aspects of the project. They also thank Ketty Bienvenu, Lidia Saint Louis, Sergine Soyon, and Karine Verin for their invaluable assistance.; European Project: 285837,EC:FP7:REGPOT,FP7-REGPOT-2011-1,STRONGER(2011)
نبذة مختصرة : International audience ; Little information is available on the molecular epidemiologic profile of HIV-1 in French Guiana, the French department with the highest HIV/AIDS incidence. To follow the evolution of HIV-1 diversity, we carried out a molecular analysis of HIV-1 isolates from 305 treatment-naive patients between 2006 and 2012. Protease and reverse-transcriptase sequences were obtained for subtype characterization, polymorphism analysis, and identification of drug resistance mutations. Of 305 HIV-1 strains, 95.1% were subtype B viruses. The overall prevalence of transmitted drug-resistance mutations (TDRMs) was 4.6% (14/305), ranging from 1.9% to 7.1% depending on the year. This study shows a low level of HIV-1 genetic diversity and a moderate prevalence of TDRMs with no evidence of an increasing trend over the study period. Nevertheless, the strong genetic polymorphism observed on both genes may be of concern for long-term treatment of people living with HIV-1 and thus deserves continuous monitoring.
Processing Request
No Comments.